Articles with public access mandates - Keith A Johnson - UK Medical Research CouncilLearn more
NoteFor this mandate, articles should be available from specific locations.
OverallDFGFWOSFIDSTFWFFNRSNIHGovernment of SpainGovernment of ItalyNSFCFCTEuropean CommissionSTFCAcademy of FinlandDOECSIRNSFNKFIBELSPOMESTDOTKAMTACASHelmholtzBMBFSNSFTUBITAKNCNCIHRDoDFAPESPMRCNHMRCNIHRSwedish Research CouncilARCNSERCHHMIWellcomeFRQSNWOUK Research & InnovationKnut and Alice Wallenberg FoundationGovernment of ArgentinaDFFDNRFNRFARRSRCNDoris Duke Charitable FoundationResearch Grants Council, Hong KongRoyal Society UKParkinson's Foundation, USAAHAGenome CanadaINSERMMarianne and Marcus Wallenberg FoundationAlzheimers's UKBBSRCEPSRCZonMwANRUSAIDHSFBanking Foundation "la Caixa"HRBCancer Research UKCanada First Research Excellence FundGatesFordNASAVAEMBLBHFDMTState of CalifoniaFRQNTNMRCMichael J Fox FoundationMQ Mental Health ResearchCZI
Available based on mandate: 24
Plasma p‐tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's disease
D Aguillon, S Langella, Y Chen, JS Sanchez, Y Su, C Vila‐Castelar, ...
Alzheimer's & Dementia 19 (6), 2585-2594, 2023
Characterizing heterogeneity in neuroimaging, cognition, clinical symptoms, and genetics among patients with late-life depression
J Wen, CHY Fu, D Tosun, Y Veturi, Z Yang, A Abdulkadir, E Mamourian, ...
JAMA psychiatry 79 (5), 464-474, 2022
Brain charts for the human lifespan
RAI Bethlehem, J Seidlitz, SR White, JW Vogel, KM Anderson, ...
Nature 604 (7906), 525-533, 2022
Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum
WJ Jansen, O Janssen, BM Tijms, SJB Vos, R Ossenkoppele, PJ Visser, ...
JAMA neurology 79 (3), 228-243, 2022
Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study
JP Chhatwal, SA Schultz, E McDade, AP Schultz, L Liu, BJ Hanseeuw, ...
The Lancet Neurology 21 (2), 140-152, 2022
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ...
The Lancet Infectious Diseases 22 (1), 35-42, 2022
The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
TI de Silva, G Liu, BB Lindsey, D Dong, SC Moore, NS Hsu, D Shah, ...
Iscience 24 (11), 2021
In vivo rate-determining steps of tau seed accumulation in Alzheimer’s disease
G Meisl, E Hidari, K Allinson, T Rittman, SL DeVos, JS Sanchez, CK Xu, ...
Science advances 7 (44), eabh1448, 2021
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7
B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ...
Cell reports 35 (13), 2021
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study
MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ...
The Lancet Public Health 6 (5), e335-e345, 2021
Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non‐demented individuals with autosomal‐dominant Alzheimer's disease
E Guzmán‐Vélez, H Zetterberg, JT Fox‐Fuller, C Vila‐Castelar, ...
Alzheimer's & Dementia 17 (5), 813-821, 2021
Longitudinal accumulation of cerebral microhemorrhages in dominantly inherited Alzheimer disease
N Joseph-Mathurin, G Wang, K Kantarci, CR Jack Jr, E McDade, ...
Neurology 96 (12), e1632-e1645, 2021
Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity
E Volz, V Hill, JT McCrone, A Price, D Jorgensen, Á O’Toole, J Southgate, ...
Cell 184 (1), 64-75. e11, 2021
Serum neurofilament light chain levels are associated with white matter integrity in autosomal dominant Alzheimer's disease
SA Schultz, JF Strain, A Adedokun, Q Wang, O Preische, J Kuhle, S Flores, ...
Neurobiology of disease 142, 104960, 2020
Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report
JF Arboleda-Velasquez, F Lopera, M O’Hare, S Delgado-Tirado, C Marino, ...
Nature medicine 25 (11), 1680-1683, 2019
Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer's disease
Z Chen, D Mengel, A Keshavan, RA Rissman, A Billinton, M Perkinton, ...
Alzheimer's & Dementia 15 (3), 487-496, 2019
White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer’s disease
S Lee, ME Zimmerman, A Narkhede, SE Nasrabady, G Tosto, IB Meier, ...
PLoS One 13 (5), e0195838, 2018
Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits
Y Deming, J Xia, Y Cai, J Lord, JL Del-Aguila, MV Fernandez, D Carrell, ...
Scientific Reports 6 (1), 18092, 2016
Massachusetts Alzheimer's disease research center: progress and challenges
BT Hyman, JH Growdon, MW Albers, RL Buckner, J Chhatwal, ...
Alzheimer's & Dementia 11 (10), 1241-1245, 2015
Invited review: Frontotemporal dementia caused by microtubule‐associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging
B Ghetti, AL Oblak, BF Boeve, KA Johnson, BC Dickerson, M Goedert
Neuropathology and applied neurobiology 41 (1), 24-46, 2015
Publication and funding information is determined automatically by a computer program